[
  {
    "ts": null,
    "headline": "Stocks to Watch Friday: Applied Materials, Nvidia, Warner Bros.",
    "summary": "↘️ Applied Materials (AMAT): The chip-equipment maker's quarterly results and forecasts for this quarter topped expectations, spurred by the AI boom. Shares skidded 5% in premarket trading, however, when a broader tech selloff looked poised to continue.",
    "url": "https://finnhub.io/api/news?id=20f39b1d92912924aed11deee31495f8cec5320268fb54fb57431db417c5deac",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763113817,
      "headline": "Stocks to Watch Friday: Applied Materials, Nvidia, Warner Bros.",
      "id": 137478207,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "↘️ Applied Materials (AMAT): The chip-equipment maker's quarterly results and forecasts for this quarter topped expectations, spurred by the AI boom. Shares skidded 5% in premarket trading, however, when a broader tech selloff looked poised to continue.",
      "url": "https://finnhub.io/api/news?id=20f39b1d92912924aed11deee31495f8cec5320268fb54fb57431db417c5deac"
    }
  },
  {
    "ts": null,
    "headline": "Novo’s New Chairman Urged to Curb Risk After Metsera Drama",
    "summary": "Investors are meeting on Friday to elect Lars Rebien Sorensen to lead the supervisory board less than a week after Novo lost a bidding war with Pfizer Inc. The outcome is a foregone conclusion as the Dane, who ran the company for 16 years, also heads the Novo Nordisk Foundation, the controlling shareholder that holds 77% of Novo’s voting rights.",
    "url": "https://finnhub.io/api/news?id=1867aa0fc4be71707d05d327718175fabfcade42038e83524e166c35e772532f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763106069,
      "headline": "Novo’s New Chairman Urged to Curb Risk After Metsera Drama",
      "id": 137478327,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investors are meeting on Friday to elect Lars Rebien Sorensen to lead the supervisory board less than a week after Novo lost a bidding war with Pfizer Inc. The outcome is a foregone conclusion as the Dane, who ran the company for 16 years, also heads the Novo Nordisk Foundation, the controlling shareholder that holds 77% of Novo’s voting rights.",
      "url": "https://finnhub.io/api/news?id=1867aa0fc4be71707d05d327718175fabfcade42038e83524e166c35e772532f"
    }
  },
  {
    "ts": null,
    "headline": "Can Lilly's Next-Gen Obesity Drugs Help Sustain Its Market Dominance?",
    "summary": "Eli Lilly's next-gen obesity drugs, led by oral orforglipron and triple-acting retatrutide, aim to reshape the fast-growing weight-loss market.",
    "url": "https://finnhub.io/api/news?id=09e66a8198c714a21778e545d85abe0babd6b1c075bfafd8ffe8045466ae9502",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763128380,
      "headline": "Can Lilly's Next-Gen Obesity Drugs Help Sustain Its Market Dominance?",
      "id": 137480128,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly's next-gen obesity drugs, led by oral orforglipron and triple-acting retatrutide, aim to reshape the fast-growing weight-loss market.",
      "url": "https://finnhub.io/api/news?id=09e66a8198c714a21778e545d85abe0babd6b1c075bfafd8ffe8045466ae9502"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Roundup: Cisco Surges, Oracle Sinks Amid Growing AI Fears",
    "summary": "Market mood is mercurial and jittery. Cisco vs. Oracle: a split in AI infrastructure plays.",
    "url": "https://finnhub.io/api/news?id=8e15994140831b7df83a365386b0e3951e0e442cd0352a0b705eb5b8a92f36fa",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763127900,
      "headline": "Wall Street Roundup: Cisco Surges, Oracle Sinks Amid Growing AI Fears",
      "id": 137481256,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1193524207/image_1193524207.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Market mood is mercurial and jittery. Cisco vs. Oracle: a split in AI infrastructure plays.",
      "url": "https://finnhub.io/api/news?id=8e15994140831b7df83a365386b0e3951e0e442cd0352a0b705eb5b8a92f36fa"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Novo Nordisk disown Mangoceuticals’ GLP-1RA partnership claim",
    "summary": "The two drugmakers swiftly denied any affiliation with Mangoceuticals, who claimed it had partnered with them.",
    "url": "https://finnhub.io/api/news?id=9afdbaa705640c14d44d832cd5a79849329de3a9b21e43971782c1ba4640415b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763125241,
      "headline": "Eli Lilly and Novo Nordisk disown Mangoceuticals’ GLP-1RA partnership claim",
      "id": 137480129,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The two drugmakers swiftly denied any affiliation with Mangoceuticals, who claimed it had partnered with them.",
      "url": "https://finnhub.io/api/news?id=9afdbaa705640c14d44d832cd5a79849329de3a9b21e43971782c1ba4640415b"
    }
  },
  {
    "ts": null,
    "headline": "Pharma ETFs in Spotlight Following Robust Q3 Earnings Results",
    "summary": "Pharma ETFs like IHE and PPH are rallying as strong Q3 earnings across major pharmaceutical companies lift sector sentiment.",
    "url": "https://finnhub.io/api/news?id=469476e1c5e3b37cd8290dd50c679e28e3d6eb5ae8047acb8f21f3f31eca06ee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763125140,
      "headline": "Pharma ETFs in Spotlight Following Robust Q3 Earnings Results",
      "id": 137480131,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Pharma ETFs like IHE and PPH are rallying as strong Q3 earnings across major pharmaceutical companies lift sector sentiment.",
      "url": "https://finnhub.io/api/news?id=469476e1c5e3b37cd8290dd50c679e28e3d6eb5ae8047acb8f21f3f31eca06ee"
    }
  },
  {
    "ts": null,
    "headline": "Zacks Investment Ideas feature highlights: IWM, CoreWeave, Astera Labs, Nebius, Expand Energy, Eli Lilly and Nvidia",
    "summary": "Zacks Investment Ideas tracks market shifts as IWM strength, AI stock rotation and Nvidia's key support test shape year-end positioning.",
    "url": "https://finnhub.io/api/news?id=f7b5490bee232234ea7cd72b664eb199fb62c2198162231e3b579c8811b2d693",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763123820,
      "headline": "Zacks Investment Ideas feature highlights: IWM, CoreWeave, Astera Labs, Nebius, Expand Energy, Eli Lilly and Nvidia",
      "id": 137480132,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Zacks Investment Ideas tracks market shifts as IWM strength, AI stock rotation and Nvidia's key support test shape year-end positioning.",
      "url": "https://finnhub.io/api/news?id=f7b5490bee232234ea7cd72b664eb199fb62c2198162231e3b579c8811b2d693"
    }
  },
  {
    "ts": null,
    "headline": "Why Is Everyone Talking About Novo Nordisk Stock?",
    "summary": "There is hardly a dull moment for the drugmaker these days.",
    "url": "https://finnhub.io/api/news?id=8a364b38c1fd913b55d3198d85c1bcdc3ef8d8caadfbe486cc22523a51289d5f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763118900,
      "headline": "Why Is Everyone Talking About Novo Nordisk Stock?",
      "id": 137478264,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "There is hardly a dull moment for the drugmaker these days.",
      "url": "https://finnhub.io/api/news?id=8a364b38c1fd913b55d3198d85c1bcdc3ef8d8caadfbe486cc22523a51289d5f"
    }
  },
  {
    "ts": null,
    "headline": "Elanco Animal Health: What A Difference An Innovation Year Makes",
    "summary": "Elanco Animal Health rebounds with strong organic growth and innovation. Discover if recent gains mean it's time to invest or wait.",
    "url": "https://finnhub.io/api/news?id=b591e805d378e3af744551188059d163406ed34e036b0c120d42c13e40ef5e55",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763114428,
      "headline": "Elanco Animal Health: What A Difference An Innovation Year Makes",
      "id": 137479162,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1380983320/image_1380983320.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Elanco Animal Health rebounds with strong organic growth and innovation. Discover if recent gains mean it's time to invest or wait.",
      "url": "https://finnhub.io/api/news?id=b591e805d378e3af744551188059d163406ed34e036b0c120d42c13e40ef5e55"
    }
  },
  {
    "ts": null,
    "headline": "Medicxi Announces €500 Million Fund V",
    "summary": "Medicxi, a leading European life sciences venture capital firm, today announced the closing of Medicxi V, a €500 million fund dedicated to building and backing innovative biotechnology companies with clear product visions to transform patient care. The oversubscribed fund closed with strong support from existing limited partners and a select group of new institutional investors. The Fund will focus on Medicxi's pioneering asset-centric investment model.",
    "url": "https://finnhub.io/api/news?id=74961d3eb6fe4fadfc757f36945bd3e1bd27b2e0eb676f6d31aaf7aa886d901d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763107200,
      "headline": "Medicxi Announces €500 Million Fund V",
      "id": 137478265,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Medicxi, a leading European life sciences venture capital firm, today announced the closing of Medicxi V, a €500 million fund dedicated to building and backing innovative biotechnology companies with clear product visions to transform patient care. The oversubscribed fund closed with strong support from existing limited partners and a select group of new institutional investors. The Fund will focus on Medicxi's pioneering asset-centric investment model.",
      "url": "https://finnhub.io/api/news?id=74961d3eb6fe4fadfc757f36945bd3e1bd27b2e0eb676f6d31aaf7aa886d901d"
    }
  },
  {
    "ts": null,
    "headline": "Netflix’s Stock Split Is Almost Here. Eli Lilly Could Be Next.",
    "summary": "The drugmaker’s stock checks all the boxes for a split. the price keeps climbing, the company is on fire, and it’s a bull market.",
    "url": "https://finnhub.io/api/news?id=68bf9136101267c110f514e7c3cc75ed436a4bc618925c5d4872d4630ce10c67",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763100900,
      "headline": "Netflix’s Stock Split Is Almost Here. Eli Lilly Could Be Next.",
      "id": 137476727,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The drugmaker’s stock checks all the boxes for a split. the price keeps climbing, the company is on fire, and it’s a bull market.",
      "url": "https://finnhub.io/api/news?id=68bf9136101267c110f514e7c3cc75ed436a4bc618925c5d4872d4630ce10c67"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk's shareholders approve chaotic board overhaul as weight loss market challenges loom",
    "summary": "Novo Nordisk shareholders approved the proposals to revamp the board with 93% voting in favor. The foundation controls over 75% of votes.",
    "url": "https://finnhub.io/api/news?id=959533f8f72246a44f2593734d72d3b8506bc762a25d813d9aed8b8a7b250b61",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763092111,
      "headline": "Novo Nordisk's shareholders approve chaotic board overhaul as weight loss market challenges loom",
      "id": 137479775,
      "image": "https://image.cnbcfm.com/api/v1/image/108226063-1763122756299-gettyimages-2197227432-AFP_36X97EZ.jpeg?v=1763122810&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "Novo Nordisk shareholders approved the proposals to revamp the board with 93% voting in favor. The foundation controls over 75% of votes.",
      "url": "https://finnhub.io/api/news?id=959533f8f72246a44f2593734d72d3b8506bc762a25d813d9aed8b8a7b250b61"
    }
  },
  {
    "ts": null,
    "headline": "It Looks Like Eli Lilly Will Become The Next Trillion Dollar Baby",
    "summary": "Eli Lilly is poised to become the first $1 trillion pharmaceutical company, driven by explosive growth in its weight-loss drug, Mounjaro. See why LLY stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=79c85ed4b0aef6164e6a90907d68d96b3ee76d5fbb25fc857a3a0dd62e460d1d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763086971,
      "headline": "It Looks Like Eli Lilly Will Become The Next Trillion Dollar Baby",
      "id": 137477339,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2159546970/image_2159546970.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly is poised to become the first $1 trillion pharmaceutical company, driven by explosive growth in its weight-loss drug, Mounjaro. See why LLY stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=79c85ed4b0aef6164e6a90907d68d96b3ee76d5fbb25fc857a3a0dd62e460d1d"
    }
  },
  {
    "ts": null,
    "headline": "Mangoceuticals Provides Clarification on Launch of Branded GLP-1 Weight-Management Programs",
    "summary": "Dallas, Texas, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”) is issuing the following clarification regarding its press release issued earlier this morning titled “Mangoceuticals Partners with Eli Lilly and Novo Nordisk…”. The newly launched Mangoceuticals weight-management programs MangoRx Direct and PeachesRx Direct are licensed and approved to issue, through a third-party provider, valid prescriptions for FDA-approved branded GLP-1 m",
    "url": "https://finnhub.io/api/news?id=3be49d40f0b294def783e9cad3289c2b0151d62b0b9d5211079eba11991d91e2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763080620,
      "headline": "Mangoceuticals Provides Clarification on Launch of Branded GLP-1 Weight-Management Programs",
      "id": 137475598,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Dallas, Texas, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) (“Mangoceuticals” or the “Company”) is issuing the following clarification regarding its press release issued earlier this morning titled “Mangoceuticals Partners with Eli Lilly and Novo Nordisk…”. The newly launched Mangoceuticals weight-management programs MangoRx Direct and PeachesRx Direct are licensed and approved to issue, through a third-party provider, valid prescriptions for FDA-approved branded GLP-1 m",
      "url": "https://finnhub.io/api/news?id=3be49d40f0b294def783e9cad3289c2b0151d62b0b9d5211079eba11991d91e2"
    }
  },
  {
    "ts": null,
    "headline": "Morgan Stanley Maintains Eli Lilly and (LLY) Overweight Recommendation",
    "summary": "Morgan Stanley Maintains Eli Lilly and (LLY) Overweight Recommendation",
    "url": "https://finnhub.io/api/news?id=748961c49da64e0c9a0e573a5acdf1c045b87b01a254dd57d98f539d3dd21dae",
    "source": "Fintel",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1763078913,
      "headline": "Morgan Stanley Maintains Eli Lilly and (LLY) Overweight Recommendation",
      "id": 137474902,
      "image": "",
      "related": "LLY",
      "source": "Fintel",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=748961c49da64e0c9a0e573a5acdf1c045b87b01a254dd57d98f539d3dd21dae"
    }
  }
]